Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Carcinoma, Renal Cell 15Melanoma 12HIV Infections 6Acquired Immunodeficiency Syndrome 6Sarcoma, Kaposi 5Lymphoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Triple Negative Breast Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Leukemia, Myeloid, Chronic-Phase 2Leukemia 2Kidney Neoplasms 2Hematologic Neoplasms 2Uveal Melanoma 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Tumor Virus Infections 1Thrombocythemia, Essential 1Solid Cancers 1Skin Neoplasms 1Sarcoma 1Polycythemia Vera 1Peritoneal Neoplasms 1Papillomavirus Infections 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1

Interventions

romidepsin 12Cyclophosphamide 11Vincristine 9Rituximab 9Etoposide 9Lenalidomide 8Doxorubicin 8Brentuximab Vedotin 8fludarabine 6Prednisone 6Peripheral Blood Stem Cell Transplantation 6Melphalan 6Depsipeptides 6fludarabine phosphate 5Mycophenolic Acid 5Lactones 5Gemcitabine 5Cytarabine 5Bendamustine Hydrochloride 5Antilymphocyte Serum 5Whole-Body Irradiation 4Tacrolimus 4Sirolimus 4Methotrexate 4MLN 8237 4Carmustine 4Bortezomib 410-propargyl-10-deazaaminopterin 4thymoglobulin 3duvelisib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, T-Cell × Interferon alpha-2 × Clear all
NCT00038376 2018-10-29

Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies

M.D. Anderson Cancer Center

Phase 2 Completed
56 enrolled
LymphoidOther hematologic neoplasm

Mycosis Fungoides, Lymphoma, T-Cell, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡